Genzyme to divest diagnostics business to Sekisui Chemical
Sekisui will purchase substantially all of the assets of the business, including diagnostic product lines and technologies. The business will be operated as part of Sekisui Medical Co,
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.